iTeos Therapeutics, Inc. (ITOS)
Stock Price:
$26.80 USD
-1.77 (-6.20%)
Updated November 30, 2:36 PM EST - Market open
Key Info
| Market Cap |
939.20M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
n/a |
| Shares Out |
35.04M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 30 |
| Last Price |
$26.80 |
| Previous Close |
$28.57 |
| Change ($) |
-1.77 |
| Change (%) |
-6.20% |
| Day's Open |
28.22 |
| Day's Range |
26.50 - 29.00 |
| Day's Volume |
202,341 |
| 52-Week Range |
17.57 - 32.92 |
More Stats
| Market Cap |
939.20M |
| Enterprise Value |
599.09M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
35.04M |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
353,526 |
| Short Ratio |
3.26 |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.98 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
340.11M |
| Net Cash / Share |
9.70 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (5)
| Buy |
4 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$43.60*
(62.69% upside)
Low
37.0
Current: $26.80
High
50.0
Target: 43.60
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -28.05 | -21.50 |
| Net Income | -22.45 | -18.06 |
| Shares Outstanding | 0.67 | 0.62 |
| Earnings Per Share | -39.51 | -32.63 |
| Operating Cash Flow | -23.15 | -19.10 |
| Capital Expenditures | -0.72 | -0.23 |
| Free Cash Flow | -23.87 | -19.32 |
| Cash & Equivalents | 19.99 | 22.05 |
| Net Cash / Debt | 19.99 | 22.05 |
| Assets | 30.74 | 27.39 |
| Liabilities | 15.08 | 12.34 |
| Book Value | -36.09 | -10.68 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
iTeos Therapeutics, Inc. |
| Country |
United States |
| Employees |
55 |
| CEO |
Michel Detheux |
Stock Information
| Ticker Symbol |
ITOS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ITOS |
| IPO Date |
July 24, 2020 |
Description
Iteos Therapeutics, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts.